TP53 and cancer: Interestingly, our findings revealed that exogenous DCN did not significantly downregulate the MDM2 expression level in cancer cells (Figure 4B), yet enhanced activation and stabilization of p53 were observed in dE1/DCN-treated cells (Figure 4C and 4D).